UY27598A1 - Composiciones farmacéuticas de derivados de taxano oralmente activos que tienen biodisponibilidad mejorada - Google Patents

Composiciones farmacéuticas de derivados de taxano oralmente activos que tienen biodisponibilidad mejorada

Info

Publication number
UY27598A1
UY27598A1 UY27598A UY27598A UY27598A1 UY 27598 A1 UY27598 A1 UY 27598A1 UY 27598 A UY27598 A UY 27598A UY 27598 A UY27598 A UY 27598A UY 27598 A1 UY27598 A1 UY 27598A1
Authority
UY
Uruguay
Prior art keywords
pharmaceutical compositions
orxally
active
biodisponibility
improved
Prior art date
Application number
UY27598A
Other languages
English (en)
Inventor
Joseph Ballard Bogardus
Robert Kevin Perrone
Krishnaswams S Raghavan
Sailesh A Varia
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of UY27598A1 publication Critical patent/UY27598A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epoxy Compounds (AREA)

Abstract

Se describen las composiciones farmacéuticas que comprenden un derivado de taxano oralmente activo y un agente de solubilización farmacéuticamente aceptable, y que proporcionan absorción oral efectiva y consistente del derivado de taxano.
UY27598A 2001-12-20 2002-12-20 Composiciones farmacéuticas de derivados de taxano oralmente activos que tienen biodisponibilidad mejorada UY27598A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34288901P 2001-12-20 2001-12-20

Publications (1)

Publication Number Publication Date
UY27598A1 true UY27598A1 (es) 2003-07-31

Family

ID=23343716

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27598A UY27598A1 (es) 2001-12-20 2002-12-20 Composiciones farmacéuticas de derivados de taxano oralmente activos que tienen biodisponibilidad mejorada

Country Status (24)

Country Link
US (1) US20030220391A1 (es)
EP (1) EP1465618A2 (es)
JP (1) JP2006501134A (es)
KR (1) KR20040066921A (es)
CN (1) CN1273130C (es)
AR (1) AR037951A1 (es)
AU (1) AU2002361701A1 (es)
BR (1) BR0215184A (es)
CA (1) CA2470826A1 (es)
GE (1) GEP20063806B (es)
HR (1) HRP20040545A2 (es)
HU (1) HUP0500843A2 (es)
IL (1) IL162118A0 (es)
IS (1) IS7306A (es)
MX (1) MXPA04005877A (es)
NO (1) NO20043101L (es)
PE (1) PE20030742A1 (es)
PL (1) PL374283A1 (es)
RS (1) RS52904A (es)
RU (1) RU2004119557A (es)
TW (1) TW200302086A (es)
UY (1) UY27598A1 (es)
WO (1) WO2003053350A2 (es)
ZA (1) ZA200404584B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050106122A1 (en) * 2002-02-25 2005-05-19 Sveinbjorn Gizurarson Absorption enhancing agent
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
KR100533458B1 (ko) 2002-07-20 2005-12-07 대화제약 주식회사 파클리탁셀의 가용화용 조성물 및 그의 제조 방법
EP1498120A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Semi-solid formulations for the oral administration of taxoids
CN1886400A (zh) 2003-09-25 2006-12-27 泰普斯特医药公司 9,10－α,α－OH紫杉烷类似物及其制备方法
US20060088591A1 (en) * 2004-10-22 2006-04-27 Jinghua Yuan Tablets from a poorly compressible substance
US20060116420A1 (en) * 2004-11-23 2006-06-01 Ramakrishnan Chidambaram Crystalline forms of 3'-tert-Butyl-3'-N-tert-butyloxycarbonyl-4-deacetyl-3'-dephenyl-3'-N-debenzoyl-4-O-methoxycarbonyl-paclitaxel
CA2598213C (en) * 2005-02-18 2011-04-19 Abraxis Bioscience, Inc. Drugs with improved hydrophobicity for incorporation in medical devices
AU2012202903B2 (en) * 2005-02-18 2014-12-11 Abraxis Bioscience, Inc. Drugs with improved hydrophobicity for incorporation in medical devices
BRPI0613005A8 (pt) 2005-07-15 2017-12-26 Angiochem Inc uso de polipeptídeos de aprotinina como veículos em conjugados farmacêuticos.
US20070015834A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing PEG/Poloxamer
HUE048521T2 (hu) 2005-08-31 2020-08-28 Abraxis Bioscience Llc Gyengén vízoldékony gyógyszerészeti és antimikrobális hatóanyagokat tartalmazó keverékek
WO2007134354A1 (de) * 2006-05-23 2007-11-29 Ebewe Pharma Ges.M.B.H. Nfg. Kg Pharmazeutische formulierung
US11786504B2 (en) 2006-09-28 2023-10-17 Tapestry Pharmaceuticals, Inc. Taxane analogs for the treatment of brain cancer
WO2008106621A1 (en) * 2007-02-28 2008-09-04 Tapestry Pharmaceuticals, Inc Taxane analogs for the treatment of brain cancer
US11873308B2 (en) 2006-11-06 2024-01-16 Tapestry Pharmaceuticals, Inc. Biologically active taxane analogs and methods of treatment by oral administration
WO2008121476A1 (en) 2007-03-28 2008-10-09 Tapestry Pharmaceuticals, Inc. Biologically active taxane analogs and methods of treatment by oral administration
EP1946747A1 (en) * 2007-01-17 2008-07-23 Sandoz AG Pharmaceutical composition of improved stability containing taxane derivatives
EP2190413B1 (en) * 2007-08-24 2015-01-28 Stichting Het Nederlands Kanker Instituut Compositions for the treatment of neoplastic diseases
US9089544B2 (en) * 2007-08-24 2015-07-28 Slotervaart Participaties Bv Composition
BRPI0820198A2 (pt) * 2007-11-12 2019-09-24 Novartis Ag composições farmacêuticas
EP2077132A1 (en) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispensing device, storage device and method for dispensing a formulation
ES2344674B1 (es) 2008-08-07 2011-06-29 Gp Pharm, S.A. Composicion farmaceutica inyectable de taxanos.
RU2011118056A (ru) 2008-10-15 2012-11-27 Ангиокем Инк. Конъюгаты агонистов glp-1 и их применение
EP2662472B1 (de) 2009-03-31 2019-02-27 Boehringer Ingelheim International Gmbh Verfahren zur Beschichtung einer Oberfläche eines Bauteils
US9265910B2 (en) 2009-05-18 2016-02-23 Boehringer Ingelheim International Gmbh Adapter, inhalation device, and nebulizer
CN102038635A (zh) 2009-10-23 2011-05-04 天津天士力集团有限公司 一种含有pH值调节剂的紫杉烷类药物溶液及其制备方法
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
WO2011064163A1 (en) 2009-11-25 2011-06-03 Boehringer Ingelheim International Gmbh Nebulizer
UA107097C2 (en) 2009-11-25 2014-11-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Dispenser
JP5874724B2 (ja) 2010-06-24 2016-03-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
EP2694220B1 (de) 2011-04-01 2020-05-06 Boehringer Ingelheim International GmbH Medizinisches gerät mit behälter
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
WO2013152894A1 (de) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Zerstäuber mit kodiermitteln
EP2777691A1 (en) * 2013-03-14 2014-09-17 Pharmachemie B.V. Taxoid - Purification of Liquid Excipients
JP6643231B2 (ja) 2013-08-09 2020-02-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
EP2835146B1 (en) 2013-08-09 2020-09-30 Boehringer Ingelheim International GmbH Nebulizer
DK3139983T3 (da) 2014-05-07 2023-09-11 Boehringer Ingelheim Int Beholder og indikatoranordning, samt forstøver
HUE055604T2 (hu) 2014-05-07 2021-12-28 Boehringer Ingelheim Int Porlasztó
JP6580070B2 (ja) 2014-05-07 2019-09-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 容器、ネブライザ、及び使用
CN103980232A (zh) * 2014-06-05 2014-08-13 北京诺普德医药科技有限公司 10-乙酰基多西紫杉醇及其用途
JP6823055B2 (ja) 2015-06-15 2021-01-27 アンジオケム インコーポレーテッド 軟髄膜癌腫症の治療方法
TWI715636B (zh) * 2015-09-30 2021-01-11 香港商慧源香港創新有限公司 口服紫杉烷組合物及方法
CN108066335B (zh) * 2016-11-11 2020-02-21 北京康辰药业股份有限公司 一种含有紫杉醇或其类似物的药物组合物及其制备方法
FR3113238B1 (fr) 2020-08-05 2024-04-05 Gattefosse Sas Utilisation comme excipient, d’un melange de macrogolglyceride laurique et de polyethylene glycol

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5817321A (en) * 1992-10-08 1998-10-06 Supratek Pharma, Inc. Biological agent compositions
WO1994012031A1 (en) * 1992-11-27 1994-06-09 Napro Biotherapeutics, Inc. Injectable composition
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US6395770B1 (en) * 1995-10-26 2002-05-28 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
CN1304058C (zh) * 1996-03-12 2007-03-14 Pg－Txl有限公司 水溶性紫杉醇产品
US5756537A (en) * 1996-11-08 1998-05-26 Parkash S. Gill, M.D., Inc. Regime for paclitaxel in Kaposi's sarcoma patients
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US6515016B2 (en) * 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US5980936A (en) * 1997-08-07 1999-11-09 Alliance Pharmaceutical Corp. Multiple emulsions comprising a hydrophobic continuous phase
EP1067923A4 (en) * 1997-12-31 2002-11-13 Bristol Myers Squibb Co 2-AROYL-4-ACYL PACLITAXEL (TAXEL) ANALOGS
IL131217A0 (en) * 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
US6979456B1 (en) * 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
AU761389B2 (en) * 1999-05-17 2003-06-05 Bristol-Myers Squibb Company Novel reaction conditions for the cleavage of silyl ethers in the preparation of paclitaxel (taxol) and paclitaxel analogues
DK1206461T3 (da) * 1999-08-11 2004-08-16 Bristol Myers Squibb Co Fremgangsmåde til fremstilling af en paclitaxel C-4-methylcarbonatanalog
US6136846A (en) * 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
US6750246B1 (en) * 2000-02-03 2004-06-15 Bristol-Myers Squibb Company C-4 carbonate taxanes
US6916942B2 (en) * 2000-02-03 2005-07-12 Bristol-Myers Squibb Company Process for the preparation of C-4 carbonate taxanes
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
JP2004536026A (ja) * 2000-11-28 2004-12-02 トランスフォーム ファーマシューティカルズ，インコーポレーティッド． パクリタキセル、その誘導体、および薬剤として許容される塩を含む医薬品製剤
TWI297335B (en) * 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
AU2002357012A1 (en) * 2001-11-27 2003-06-10 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof

Also Published As

Publication number Publication date
PE20030742A1 (es) 2003-09-02
CN1606437A (zh) 2005-04-13
MXPA04005877A (es) 2004-09-13
HRP20040545A2 (en) 2005-08-31
IS7306A (is) 2004-06-10
BR0215184A (pt) 2006-06-06
KR20040066921A (ko) 2004-07-27
JP2006501134A (ja) 2006-01-12
PL374283A1 (en) 2005-10-03
GEP20063806B (en) 2006-04-25
RS52904A (en) 2006-12-15
WO2003053350A2 (en) 2003-07-03
CN1273130C (zh) 2006-09-06
HUP0500843A2 (hu) 2005-12-28
US20030220391A1 (en) 2003-11-27
AU2002361701A1 (en) 2003-07-09
NO20043101L (no) 2004-07-19
EP1465618A2 (en) 2004-10-13
ZA200404584B (en) 2005-09-13
TW200302086A (en) 2003-08-01
CA2470826A1 (en) 2003-07-03
IL162118A0 (en) 2005-11-20
AR037951A1 (es) 2004-12-22
RU2004119557A (ru) 2005-04-20
WO2003053350A3 (en) 2004-01-15

Similar Documents

Publication Publication Date Title
UY27598A1 (es) Composiciones farmacéuticas de derivados de taxano oralmente activos que tienen biodisponibilidad mejorada
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
NO20076613L (no) Farmasoytiske formuleringer og anvendelse derav
CY1115386T1 (el) Συνδυασμος αζελαστινης και μομεταζονης
LU92513I2 (fr) Sofosbuvir et ses dérivés pharmaceutiquement acceptables (solvaldi)
NO20043702L (no) 8-azaprostaglandinderivatforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel
PL372809A1 (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
NO20024891D0 (no) Farmasöytiske sammensetninger
CO5590918A2 (es) Formulaciones
CY1113462T1 (el) Μορφη δοσολογιας περιεχουσα παντοπραζολη ως δραστικο συστατικο
DK1498411T3 (da) Diketohydrazinderivatforbindelser og medikamenter indeholdende forbindelserne som den aktive bestanddel
CY1108676T1 (el) Οφθαλμικο εναιωρημα περιλαμβανον ενα οφθαλμικο φαρμακο, μια πολοξαμινη και εναν παραγοντα ρυθμισεως της τονικοτητας τυπου γλυκολης, χρηση της εν λογω συνθεσεως για την παραγωγη ενος φαρμακου για την αγωγη οφθαλμικων διαταραχων
SE0101932D0 (sv) Pharmaceutical combinations
CY1112591T1 (el) Απο του στοματος φαρμακοτεχνικες μορφες της κλαντριβινης
LU91883I2 (fr) Pradofloxacin et ses dérivés pharmaceutiquement acceptables (VERAFLOX®)
ATE357928T1 (de) Pharmazeutische zusammensetzung für thrombinpeptidderivaten
DE602006020605D1 (de) Entzündungshemmende zusammensetzungen und anwendungsverfahren
AR033293A1 (es) Composiciones y metodos para aumentar la biodisponibilidad de agentes farmaceuticos
NO20062668L (no) Orale formuleringer av desoxypeganin og anvendelser derav
NO20054346L (no) Sammensetninger og fremgangsmater for forebygging og behandling av endotoksinrelaterte sykdommer og tilstander
NO20074167L (no) Peptidiske forbindelser
ATE353231T1 (de) Pharmazeutische zusammensetzungen
NO20043314L (no) Sedative non-benzodiazepinformuleringer
RS50681B (sr) Kombinacija taksana i ciklin-zavisne kinaze
SE0203817D0 (sv) New composition

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150126